Table 3.
Co-Morbid Neuropathologic Characteristics Among 366 Brain Donors with CTE
| Total Sample (N = 366) |
CTE Stage I (n = 58) |
CTE Stage II (n = 79) |
CTE Stage III (n = 127) |
CTE Stage IV (n = 102) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| Alzheimer’s disease | 54 | 14.8 | 2 | 3.4 | 6 | 7.6 | 10 | 7.9 | 36 | 35.3 |
| Lewy body disease | ||||||||||
| Brain stem | 28 | 7.7 | 3 | 5.3 | 2 | 2.5 | 7 | 5.5 | 16 | 15.7 |
| Limbic (transitional) | 18 | 4.9 | 2 | 3.5 | 2 | 2.5 | 10 | 7.9 | 4 | 3.9 |
| Neocortical (diffuse) | 20 | 5.5 | 2 | 3.5 | 2 | 2.5 | 8 | 6.3 | 8 | 7.8 |
| Amygdala | 4 | 1.1 | 0 | -- | 0 | -- | 0 | -- | 4 | 3.9 |
| Olfactory | 10 | 2.7 | 1 | 1.8 | 2 | 2.5 | 2 | 1.6 | 5 | 4.9 |
| Frontotemporal Lobar Degeneration (FTLD) | ||||||||||
| FTLD-Tau | 19 | 5.2 | 2 | 3.4 | 3 | 3.8 | 7 | 5.5 | 7 | 7.1 |
| FTLD-TDP-43 | 23 | 6.3 | 2 | 3.4 | 5 | 6.4 | 1 | 0.8 | 15 | 14.7 |
| Motor Neuron Disease | 17 | 4.7 | 1 | 1.7 | 6 | 7.6 | 8 | 6.3 | 2 | 2.0 |
| Prion Disease | 2 | 0.5 | 0 | -- | 0 | -- | 1 | 0.8 | 1 | 1.0 |
| CERAD neuritic plaque score | ||||||||||
| No neuritic plaques | 232 | 63.6 | 51 | 89.5 | 67 | 84.8 | 89 | 70.1 | 25 | 24.5 |
| Sparse neuritic plaques | 84 | 23.0 | 5 | 8.8 | 8 | 10.1 | 28 | 22.0 | 43 | 42.2 |
| Moderate neuritic plaques | 32 | 8.8 | 1 | 1.8 | 3 | 3.8 | 6 | 4.7 | 22 | 21.6 |
| Frequent neuritic plaques | 17 | 4.7 | 0 | -- | 1 | 1.3 | 4 | 3.1 | 12 | 11.8 |
| Thal Amyloid Phase | ||||||||||
| Phase 0 | 165 | 45.7 | 44 | 77.2 | 55 | 70.5 | 59 | 46.5 | 7 | 7.1 |
| Phase 1 / 2 | 48 | 13.3 | 3 | 5.3 | 8 | 10.3 | 24 | 18.9 | 13 | 13.1 |
| Phase 3 | 42 | 11.6 | 8 | 14.0 | 6 | 7.7 | 15 | 11.8 | 13 | 13.1 |
| Phase 4/5 | 106 | 29.4 | 2 | 3.5 | 9 | 11.5 | 29 | 22.8 | 66 | 66.7 |
| Braak Staging | ||||||||||
| Stage 0 | 84 | 23.7 | 36 | 64.3 | 32 | 41.0 | 12 | 9.8 | 4 | 4.1 |
| Stage I/II | 71 | 20.1 | 13 | 23.2 | 36 | 46.2 | 17 | 13.8 | 5 | 5.2 |
| Stage III/IV | 141 | 39.8 | 6 | 10.7 | 5 | 6.4 | 80 | 65.0 | 50 | 51.5 |
| Stage V/VI | 58 | 16.4 | 1 | 1.8 | 5 | 6.4 | 14 | 11.4 | 38 | 39.2 |
| Atherosclerosis, moderate-severe | 64 | 19.2 | 3 | 5.9 | 7 | 10.0 | 20 | 18.0 | 34 | 33.3 |
| Arteriolosclerosis, moderate-severe | 161 | 44.5 | 20 | 34.5 | 19 | 25.0 | 59 | 46.5 | 63 | 62.4 |
| White Matter Rarefaction, moderate-severe | 167 | 46.5 | 17 | 29.3 | 20 | 26.3 | 57 | 46.0 | 73 | 72.3 |
Sample size for CTE Stage was 366. Sample sizes are reduced due to missing data for the following: Lewy body disease, N = 365; FTLD-tau, N = 363; FTLD-TDP-43, N = 365; Prion disease, N = 365; CERAD, N = 365; Thal Phase, N = 361; Braak Staging, N = 354; atherosclerosis, N = 334; arteriolosclerosis, N = 362; white matter rarefaction, N = 359.